← FDA DRUG APPROVALS

FDA ANDA · ANDA091264

LEVOCETIRIZINE DIHYDROCHLORIDE

Sponsor: HETERO LABS LTD III

APPLICATION
ANDA091264
TYPE
ANDA
ORIGINAL APPROVAL
2012-06-29
LATEST ACTION
2025-07-11
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LEVOCETIRIZINE DIHYDROCHLORIDEPrescription
LEVOCETIRIZINE DIHYDROCHLORIDE 5MG · TABLET · ORAL

Approval history

2025-07-11Labeling · Supplement 13 · standardAP
2019-06-28Labeling · Supplement 8 · standardAP
2019-06-28Labeling · Supplement 10 · standardAP
2017-09-18Labeling · Supplement 5 · standardAP
2015-11-24Labeling · Supplement 3 · standardAP
2013-01-30Labeling · Supplement 2 · standardAP
2012-11-29Labeling · Supplement 1 · standardAP
2012-06-29OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →